Tyligand Bioscience (TLG HK): Synthetic Expert Call Transcript (24 Aug 2026)
TSN1611 (KRAS G12D) ASCO 2026 clinical update demonstrates a strong 50.0% ORR and 90.0% DCR in response-evaluable metastatic NSCLC patients at...
87 Views
IPO Databook: Tyligand Bioscience (HK) - Aug 2026
Founded in 2017, Tyligand Bioscience Ltd. is a clinical-stage biopharmaceutical company focusing on cancer therapeutics discovery and development....
99 Views
Pre-IPO Tyligand Bioscience - Concerns on KRAS Will Directly Limit the Valuation Ceiling
​Investors wary of early KRAS G12D projects, demand higher risk premiums. Validation needed for TSN1611 and TSN222. Tyligand's valuation may not...
146 Views
Tyligand Bioscience (泰励生物) Pre-IPO: Late Entrant to the KRAS G12D Target
​China biotech Tyligand Bioscience aims to raise $100 million through Hong Kong listing with CITIC as sole sponsor. We look at its late-stage core...
436 Views
No more insights